Related Experiment Videos
Antiplatelet therapy for treatment of acute coronary syndromes
W Mazur1, G Kaluza, N S Kleiman
1Baylor College of Medicine, Houston, Texas, USA.
Insights
Aspirin and potent GP IIb-IIIa inhibitors reduce thrombotic events in acute coronary syndromes and after angioplasty. Combining these therapies further lowers risks of heart attack and ischemic complications.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Acute coronary syndromes and post-percutaneous coronary intervention share mechanisms of atherosclerotic plaque disruption and thrombus formation.
- Platelet-rich thrombi can lead to myocardial ischemia, complete occlusion, or distal embolization.
- Aspirin offers mild platelet inhibition via cyclooxygenase activity, reducing myocardial infarction and post-angioplasty ischemia.
Purpose of the Study:
- To evaluate the efficacy of potent platelet aggregation inhibitors, specifically GP IIb-IIIa antagonists, in managing thrombotic complications.
- To assess the additive benefit of GP IIb-IIIa antagonists when used in conjunction with aspirin therapy.
Main Methods:
- Review of clinical data on aspirin's antiplatelet effects.
- Analysis of studies involving intravenous GP IIb-IIIa antagonists.
- Comparison of outcomes in patients receiving aspirin alone versus aspirin plus GP IIb-IIIa inhibitors.
Main Results:
- Aspirin reduces myocardial infarction rates in acute coronary syndromes and ischemic complications post-angioplasty.
- GP IIb-IIIa antagonists profoundly inhibit platelet aggregation by blocking the GP IIb-IIIa fibrinogen interaction.
- Combination therapy with aspirin and GP IIb-IIIa antagonists further reduces peri-interventional and recurrent myocardial infarctions.
Conclusions:
- Potent GP IIb-IIIa inhibitors provide significant additional benefit beyond aspirin in preventing thrombotic events.
- Combined antiplatelet therapy is crucial for managing high-risk patients with acute coronary syndromes and those undergoing percutaneous coronary intervention.
Abstract:
Acute coronary syndromes and the postpercutaneous coronary intervention state share the common feature of atherosclerotic plaque disruption and subsequent intraluminal thrombus formation. In most cases, vascular patency is maintained but partial occlusion causes myocardial ischemia and can either progress to complete occlusion or result in distal embolization with subsequent small vessel obstruction, the core section of an intraarterial thrombus is platelet-rich and can serve as a nidus for further thrombosis. Aspirin, by virtue of its anticycloxygenase activity inhibits platelet activation and aggregation to a mild degree. Clinically, aspirin has been shown to reduce the rates of myocardial infarction in patients with acute coronary syndromes and to reduce the number of ischemic complications which follow coronary angioplasty. More potent inhibitors of platelet aggregation antagonize the interaction between the platelet surface protein GP IIb-IIIa and fibrinogen. The result is profound inhibition of platelet aggregation. Three intravenous antagonists of platelet GP IIb-IIIa are clinically available and a fourth is under phase III study. When used in addition to aspirin therapy, these agents have been shown to produce further reductions in either peri-interventional infarctions or in recurrent myocardial infarctions in patients with acute coronary syndromes.